Core Insights - Radiopharm Theranostics has completed enrollment for the second cohort in the Phase 1 trial of 177Lu-RAD204, which targets PD-L1 positive advanced cancers, marking a significant milestone for the company [1][2] - The Data and Safety Monitoring Committee has approved advancing to a higher dose of 90mCi for the third cohort of patients [2] - The trial aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and preliminary anti-tumor activities of 177Lu-RAD204 in patients with metastatic solid tumors [2][3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][5] - The company is listed on both ASX (RAD) and NASDAQ (RADX) and has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors [5] - The company’s technology platform spans peptides, small molecules, and monoclonal antibodies for cancer treatment [5] Product Details - 177Lu-RAD204 is a single-domain monoclonal antibody that targets PD-L1, which is overexpressed in many solid tumors, making it a promising therapeutic target [3][4] - Previous Phase 1 imaging data indicated that the diagnostic compound is safe and has acceptable dosimetry in NSCLC patients [3]